AtriCure, Inc. (ATRC)

Market Cap	1.89B
Revenue (ttm)	330.38M
Net Income (ttm)	-46.47M
Shares Out	46.57M
EPS (ttm)	-1.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	189,245
Open	40.39
Previous Close	40.45
Day's Range	39.98 - 41.05
52-Week Range	32.51 - 68.58
Beta	1.31
Analysts	Buy
Price Target	59.16 (+45.57%)
Earnings Date	May 2, 2023

About ATRC

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and ...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Aug 5, 2005
• Employees: 875
• Stock Exchange: NASDAQ
• Ticker Symbol: ATRC

Analyst Forecast

According to 13 analysts, the average rating for ATRC stock is "Buy." The 12-month stock price forecast is $59.16, which is an increase of 45.57% from the latest price.

Price Target

$59.16

(45.57% upside)

Analyst Consensus: Buy